The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling (2023)

Peer-Reviewed Study · Alsmadi MM · 2023

Alsmadi MM, 2023: Physiologically based pharmacokinetic modelling of ritonavir-boosted lopinavir with ivermectin, predicting ivermectin plasma exposure rises of 234% to 453% when the CYP3A4 inhibitor is co-administered. It is a simulation, not a clinical measurement.

the ivermectin plasma levels were increased by a minimum of 425, 234, and 453% in adults, geriatrics, and pregnancy populations, respectively.

Alsmadi MM, 2023: Physiologically based pharmacokinetic modelling of ritonavir-boosted lopinavir with ivermectin, predicting ivermectin plasma exposure rises of 234% to 453% when the CYP3A4 inhibitor is co-administered. It is a simulation, not a clinical measurement. C6 CYP3A4 inhibition (modelled). Study type: in silico physiologically-based pharmacokinetic (PBPK) modelling study; no human subjects; Jordan (Jordan University of Science and Technology). Dose: model inputs based on standard COVID-19-era dosing of ivermectin and ritonavir-boosted lopinavir; virtual adult, geriatric and pregnancy populations. Comparator: ivermectin without LPVr. Funder and declared conflicts: not in the PubMed record. Confidence HIGH for what the paper says, but the finding is model output, not an observed clinical interaction – flagged so the record does not present a simulation as a measured 4-fold rise. Study type: other.